EULAR 2024

Subclinical PsA - where is the border?

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

Difference in axial involvement in axSpA and axPsA

Deeper B-cell depletion

JAK inhibitors in GCA - a good opportunity?

Handling cardiovascular risks in RA

Tapering or even stopping TNF inhibitors in pts. with sustained remission?!

Neuroinflammation as possible cause of intestinal dysbiosis in axSpA

Avoiding overdiagnosis in axSpA

Factors associated with spinal progression in axSpA

Treat-to-target approach to induce sustained clinical remission in early axSpA

Uterine inflammation in the pathogenesis in axSpA

Minimal spinal radiographic progression with Bimekizumab

Treat-to-target in axSpA - a long way to go!

Sooner or later - when therapy with biologics?

What advances the radiographic progression? IL-17A vs. TNF inhibition

Früher oder später - wann Therapie mit Biologika?

Ruolo dell’infiammazione uterina nella patogenesi dell’axSpA

Approccio treat-to-target per indurre una remissione clinica sostenuto in early axSpA

Minimale Röntgenprogression der Wirbelsäule unter Bimekizumab

Vermeidung von Überdiagnose bei axSpA

Was treibt die Röntgenprogression an? IL-17A vs. TNF Inhibition

Ruolo della neuroinfiammazione della patogensi dell’AxSpA

Treat-to-target bei der axSpA - a long way to go!

Tyk2 inhibition in PsA - a new opportunity?

IL-17 inhibition & new molecules

Subclinical PsA - where is the border?

Difference in axial involvement in axSpA and axPsA

Treatment strategy in early PsA - TnF inhibitors or not?

A lot of steroids always help - no matter the concomitant medication...

Small molecules with a better enthesitis efficacy - new data on izokibep

Which treatment to prevent PsA from PsO?

A mouse model for PsA and PsO!

Managing comorbidities in PsA

12-weeks results from the PRO-SPIRIT study

A new injection for knee osteoarthritis

Cardiovascular outcome in PsA - TnF vs. IL-17 inhibitors

The JAK family is growing. Another Tyk2 inhibitor: safe - with a moderate effect

Sonelokimab, a new molecule for IL-17A & IL-17F inhibition - first data on arthritis

The difficult cases in PsA

Early prediction by FAPI-PET in PsA

Post-hoc analysis on severe disease activity in PsA

Kleine Moleküle mit besserer Enthesitiswirkung - neue Daten zu Izokibep

Die JAK-Familie wächst. Ein weiterer Tyk2-Inhibitor: sicher - mit moderatem Effekt

Rhumatisme psoriasique débutant : anti TNF ou pas?

Viel Kortison hilft immer - Begleittherapie egal...

Valutazione della risposta a due anni di trattamento nei pazienti con Artrite Psoriasica con elevata attività di malattia

Frühe Prädiktion durch FAPI-PET bei PsA

Risultati a 12 settimane dello studio di Real World "PRO-SPIRIT"

Quel traitement pour prévenir l’évolution du psoriasis vers un rhumatisme psoriasique?

Risque cardiovasculaire et rhumatisme psoriasique : anti TNF ou anti Interleukine 17?

Sonelokimab, ein neues Molekül zur IL-17A- & IL-17F-Inhibition - erste Daten zur Arthritis

Tapering or even stopping TNF inhibitors in pts. with sustained remission?!

Deeper B-cell depletion

JAK inhibitors in GCA - a good opportunity?

Handling cardiovascular risks in RA

Real-world data on safety of etanercept biosimilar

New JAK inhibitor tested in a Phase III trial in China

Debate on regulatory safety measures for JAKies based on ORAL Surveillance study

Abatacept vs adalimumab in dual seropositive RA patients with the shared epitope

Statins in RA - who benefits?

Tapering of TNF Inhibitors in RA Patients with sustained Remission

No new safety signals from the JAK-POT study

Potential new treatment class in RA

Anti-citrullinated protein antibody (ACPA) does not predict response to abatacept in RA

Good news in RA

Debate on therapeutic drug monitoring

ARCTIC REWIND - Tapering not recommended in patients on TNF inhibitors in stable remission

A model to predict progression from palindromic rheumatism to persistent arthritis

Debatt om bruk av therapeutic drug monitoring (TDM, monitorering av legemiddelkonsentrasjoner) i klinisk praksis

Debatt om regulatoriske krav om sikkerhet ved bruk av JAK hemmere basert på den publiserte ORAL Surveillance study

ARCTIC REWIND – dosereduksjon og seponering anbefales ikke hos pasienter i stabil remisjon under behandling med en TNF-hemmer

Un modelo para predecir la progresión del reumatismo palindrómico a artritis persistente

Keine neuen Safety-Signale aus der JAK-POT Studie

Reducción y suspensión de los inhibidores del TNF en pacientes con AR en remisión mantenida

Abatacept vs adalimumab en pacientes con AR doble seropositivos con el epitopo compartido

Statine bei der RA - wer profitiert?

En ny JAK hemmer undersøkt i en fase III studie I Kina

Upadacitinib in GCA

Upadacitinib bei RZA

Holistic view on multidisciplinary care in rheumatology

AI in rheumatology

The role of rheumatoid factor from early to late

Daratumumab in SLE

How to treat Lupus: What's on the horizon?

Daratumumab bei SLE